Skip to main content
Erschienen in: Endocrine 2/2022

07.10.2022 | Original Article

Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors

verfasst von: Maxime Lelièvre, Elizabeth Katherine Anna Triumbari, Hedia Brixi, Marine Perrier, Guillaume Cadiot, Sophie Deguelte, David Morland

Erschienen in: Endocrine | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bone metastases (BM) affect 10–30% of patients with small intestine neuroendocrine tumors (siNET), but little descriptive data are available regarding their distribution throughout the skeleton or potential risk factors. Aim of the study is to better describe the imaging characteristics, distribution, and risk factors of siNET bone metastases using 18F-FDOPA PET/CT.

Methods

All patients with well-differentiated siNET who underwent an 18F-DOPA PET/CT examination in our institution were retrospectively screened between October 2017 and February 2020. Location, SUVmax and CT density of each BM were collected. Sex, metabolic tumor volume (MTV) excluding bone, and metastatic sites other than bone were studied to determine risk factors of BM.

Results

Among the 69 patients included, 11 patients (15.9%) presented BM on 18F-FDOPA (65 metastases). The most frequently involved sites were: thoracic spine, pelvic bones and ribs. About 64% of patients presented multiple BM. On coupled CT scan, 63% of BM were not visible. Using an optimal threshold of 19.2 ml, MTV was an independent predictor of BM (p = 0.004) with a derived sensitivity of 100% [65.0–100.0] and a specificity of 70.9% [57.7–81.2]. Hepatic metastatic involvement was also a significant predictor of BM (p = 0.044).

Conclusion

The development of BM in siNETs appears to be a late event, occurring in patients with a high tumor burden and hepatic involvement. They are often multiple and predominate in the axial skeleton.
Literatur
4.
Zurück zum Zitat M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller, M. Anlauf, B. Wiedenmann, R. Salazar; Barcelona Consensus Conference participants, ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95, 157–176 (2012). https://doi.org/10.1159/000335597CrossRefPubMed M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller, M. Anlauf, B. Wiedenmann, R. Salazar; Barcelona Consensus Conference participants, ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95, 157–176 (2012). https://​doi.​org/​10.​1159/​000335597CrossRefPubMed
7.
Zurück zum Zitat W.G. Meijer, E. Veer, P.L. van der; Jager, E.J. Jagt, B.A. van der; Piers, I.P. Kema, E.G.Ede Vries, P.H.B. Willemse, Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J. Nucl. Med. 44, 184–191 (2003)PubMed W.G. Meijer, E. Veer, P.L. van der; Jager, E.J. Jagt, B.A. van der; Piers, I.P. Kema, E.G.Ede Vries, P.H.B. Willemse, Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J. Nucl. Med. 44, 184–191 (2003)PubMed
10.
Zurück zum Zitat M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo, V. Ambrosini, A. Kjaer, R. Delgado-Bolton, J. Kunikowska et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588–1601 (2017). https://doi.org/10.1007/s00259-017-3728-yCrossRefPubMed M.F. Bozkurt, I. Virgolini, S. Balogova, M. Beheshti, D. Rubello, C. Decristoforo, V. Ambrosini, A. Kjaer, R. Delgado-Bolton, J. Kunikowska et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588–1601 (2017). https://​doi.​org/​10.​1007/​s00259-017-3728-yCrossRefPubMed
11.
Zurück zum Zitat L. de Mestier, C. Lepage, E. Baudin, R. Coriat, F. Courbon, A. Couvelard, C. Do Cao, E. Frampas, S. Gaujoux, R. Gincul et al. Digestive neuroendocrine neoplasms (NEN): French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig. Liver Dis. 52, 473–492 (2020). https://doi.org/10.1016/j.dld.2020.02.011CrossRefPubMed L. de Mestier, C. Lepage, E. Baudin, R. Coriat, F. Courbon, A. Couvelard, C. Do Cao, E. Frampas, S. Gaujoux, R. Gincul et al. Digestive neuroendocrine neoplasms (NEN): French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig. Liver Dis. 52, 473–492 (2020). https://​doi.​org/​10.​1016/​j.​dld.​2020.​02.​011CrossRefPubMed
12.
Zurück zum Zitat F. Montravers, D. Grahek, K. Kerrou, P. Ruszniewski, V. de Beco, N. Aide, F. Gutman, J.-D. Grangé, J.-P. Lotz, J.-N. Talbot, Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J. Nucl. Med. 47, 1455–1462 (2006)PubMed F. Montravers, D. Grahek, K. Kerrou, P. Ruszniewski, V. de Beco, N. Aide, F. Gutman, J.-D. Grangé, J.-P. Lotz, J.-N. Talbot, Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J. Nucl. Med. 47, 1455–1462 (2006)PubMed
13.
Zurück zum Zitat K.P. Koopmans, O.C. Neels, I.P. Kema, P.H. Elsinga, W.J. Sluiter, K. Vanghillewe, A.H. Brouwers, P.L. Jager, E.G.E. de Vries, Improved staging of patients with carcinoid and islet cell tumors with 18F-Dihydroxy-Phenyl-Alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 26, 1489–1495 (2008). https://doi.org/10.1200/JCO.2007.15.1126CrossRef K.P. Koopmans, O.C. Neels, I.P. Kema, P.H. Elsinga, W.J. Sluiter, K. Vanghillewe, A.H. Brouwers, P.L. Jager, E.G.E. de Vries, Improved staging of patients with carcinoid and islet cell tumors with 18F-Dihydroxy-Phenyl-Alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 26, 1489–1495 (2008). https://​doi.​org/​10.​1200/​JCO.​2007.​15.​1126CrossRef
14.
Zurück zum Zitat A. Becherer, M. Szabó, G. Karanikas, P. Wunderbaldinger, P. Angelberger, M. Raderer, A. Kurtaran, R. Dudczak, K. Kletter, Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J. Nucl. Med. Publ. Soc. Nucl. Med. 45, 1161–1167 (2004) A. Becherer, M. Szabó, G. Karanikas, P. Wunderbaldinger, P. Angelberger, M. Raderer, A. Kurtaran, R. Dudczak, K. Kletter, Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J. Nucl. Med. Publ. Soc. Nucl. Med. 45, 1161–1167 (2004)
15.
Zurück zum Zitat F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J.-P. Lotz, P. Ruszniewski, P. Rougier, F. Duron, P. Bouchard, J.-D. Grangé et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J. Clin. Endocrinol. Metab. 94, 1295–1301 (2009). https://doi.org/10.1210/jc.2008-1349CrossRefPubMed F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J.-P. Lotz, P. Ruszniewski, P. Rougier, F. Duron, P. Bouchard, J.-D. Grangé et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J. Clin. Endocrinol. Metab. 94, 1295–1301 (2009). https://​doi.​org/​10.​1210/​jc.​2008-1349CrossRefPubMed
17.
Zurück zum Zitat A. Piccardo, F. Fiz, G. Bottoni, M. Ugolini, W. Noordzij, P. Trimboli, Head-to-head comparison between 18 F-DOPA PET/CT and 68 Ga-DOTA peptides PET/CT in detecting intestinal neuroendocrine tumours: a systematic review and meta-analysis. Clin. Endocrinol. 95, 595–605 (2021). https://doi.org/10.1111/cen.14527CrossRef A. Piccardo, F. Fiz, G. Bottoni, M. Ugolini, W. Noordzij, P. Trimboli, Head-to-head comparison between 18 F-DOPA PET/CT and 68 Ga-DOTA peptides PET/CT in detecting intestinal neuroendocrine tumours: a systematic review and meta-analysis. Clin. Endocrinol. 95, 595–605 (2021). https://​doi.​org/​10.​1111/​cen.​14527CrossRef
18.
Zurück zum Zitat E. Ouvrard, L.D. Mestier, C. Boursier, B. Lachachi, N. Sahakian, E. Chevalier, N. Mikail, J. Carullo, A. Bando-Delaunay, T. Walter et al. 18F-Fluorodihydroxyphenylalanine PET/CT at the forefront for initial and/or pre-surgical evaluation of small intestine neuroendocrine tumors. J. Nucl. Med. (2022). https://doi.org/10.2967/jnumed.122.263984 E. Ouvrard, L.D. Mestier, C. Boursier, B. Lachachi, N. Sahakian, E. Chevalier, N. Mikail, J. Carullo, A. Bando-Delaunay, T. Walter et al. 18F-Fluorodihydroxyphenylalanine PET/CT at the forefront for initial and/or pre-surgical evaluation of small intestine neuroendocrine tumors. J. Nucl. Med. (2022). https://​doi.​org/​10.​2967/​jnumed.​122.​263984
20.
Zurück zum Zitat I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher, K.M. Washington, F. Carneiro, I.A. Cree; WHO Classification of Tumours Editorial Board, The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182–188 (2020). https://doi.org/10.1111/his.13975CrossRefPubMed I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher, K.M. Washington, F. Carneiro, I.A. Cree; WHO Classification of Tumours Editorial Board, The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182–188 (2020). https://​doi.​org/​10.​1111/​his.​13975CrossRefPubMed
21.
Zurück zum Zitat B. Kos-Kudła, D. O’Toole, M. Falconi, D. Gross, G. Klöppel, A. Sundin, J. Ramage, K. Oberg, B. Wiedenmann, P. Komminoth et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 91, 341–350 (2010). https://doi.org/10.1159/000287255CrossRefPubMed B. Kos-Kudła, D. O’Toole, M. Falconi, D. Gross, G. Klöppel, A. Sundin, J. Ramage, K. Oberg, B. Wiedenmann, P. Komminoth et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 91, 341–350 (2010). https://​doi.​org/​10.​1159/​000287255CrossRefPubMed
24.
Zurück zum Zitat E. Ziu, V.K. Viswanathan, F.B. Mesfin, Spinal metastasis, (StatPearls Publishing, 2021) E. Ziu, V.K. Viswanathan, F.B. Mesfin, Spinal metastasis, (StatPearls Publishing, 2021)
Metadaten
Titel
Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors
verfasst von
Maxime Lelièvre
Elizabeth Katherine Anna Triumbari
Hedia Brixi
Marine Perrier
Guillaume Cadiot
Sophie Deguelte
David Morland
Publikationsdatum
07.10.2022
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03160-2

Weitere Artikel der Ausgabe 2/2022

Endocrine 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.